Benzinga

Benzinga

Benzinga

jueves, agosto 20

Fulcrum Therapeutics Inc

FULCNASDAQ
Trade with Public
Trade with Public
$3.91
0.041.03%
al cierre: Aug 19, 5:00 PM EST
$3.95
0.04051.04%
After hour: 6:41 PM EST
Fusiones y adquisiciones: Slate Medicines, Inc. announced it will be merged with Fulcrum Therapeutics (FULC) on Monday, August 17, 2026
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Fulcrum Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fulcrum Therapeutics (FULC).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

3Buy
5Hold
3Sell
Consensus RatingHold# Analysts11Avg. Consensus PT$8Upside to Avg. PT+102.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 3, 2026JP Morgan—DowngradeOverweight→Underweight—
Jun 2, 2026StifelJames CondulisDowngradeBuy→Hold$25→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Downgrades Fulcrum Therapeutics to Underweight

JP Morgan downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight.
Benzinga Newsdesk

This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade TMHC and SARO respectively. See more views.
Avi Kapoor

PRO
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.
Benzinga Newsdesk

PRO
Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight and lowers the price target from $23 to $3.
Benzinga Newsdesk

PRO
Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $17 to $4.
Benzinga Newsdesk

PRO
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and lowers the price target from $24 to $4.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved